Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Den direkte orale antikoagulasjonsforsøket versus warfarin etter hjertekirurgi (DANCE)

15. september 2026 oppdatert av: Population Health Research Institute

The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

Studieoversikt

Detaljert beskrivelse

Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.

Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.

In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.

The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.

A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.

Studietype

Intervensjonell

Registrering (Antatt)

3500

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • Rekruttering
        • St Vincent's Hospital Melbourne
        • Ta kontakt med:
          • Andrew Newcomb, MD
        • Hovedetterforsker:
          • Andrew Newcomb, MD
      • Parkville, Victoria, Australia, 3050
        • Har ikke rekruttert ennå
        • Royal Melbourne Hospital, University of Melbourne
        • Ta kontakt med:
          • Alistair Royse, MD
        • Hovedetterforsker:
          • Alistair Royse, MD
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2C8
        • Rekruttering
        • University of Alberta Hospital
        • Hovedetterforsker:
          • Steven Meyer, MD
        • Ta kontakt med:
          • Steven Meyer, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Rekruttering
        • University of British Columbia
        • Hovedetterforsker:
          • Erica Wang, PharmD
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Rekruttering
        • St. Boniface Hospital
        • Hovedetterforsker:
          • Michael Yamashita, MD
        • Ta kontakt med:
          • Michael Yamashita, MD
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L4L2
        • Aktiv, ikke rekrutterende
        • Saint John Regional Hospital
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
        • Rekruttering
        • Health Science Centre
        • Hovedetterforsker:
          • Hasib Hanif, MD
    • Ontario
      • Greater Sudbury, Ontario, Canada, P3E 5J1
        • Rekruttering
        • Health Sciences North Research Institute
        • Hovedetterforsker:
          • Bindu Bittira, MD
      • Hamilton, Ontario, Canada, L8L 2X2
        • Rekruttering
        • Hamilton General Hospital
        • Ta kontakt med:
      • Toronto, Ontario, Canada, M5G 2C4
        • Rekruttering
        • Toronto General Hospital
        • Ta kontakt med:
          • Vivek Rao, MD
        • Hovedetterforsker:
          • Vivek Rao, MD
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Sunnybrook Hospital
        • Ta kontakt med:
          • Stephen Fremes, MD
        • Hovedetterforsker:
          • Stephen Fremes, MD
    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Rekruttering
        • Montreal Heart Institute
        • Ta kontakt med:
          • Philippe Demers, MD
        • Hovedetterforsker:
          • Philippe Demers, MD
      • Montreal, Quebec, Canada, H4J1C5
        • Rekruttering
        • Hôpital Sacré-Coeur de Montréal
        • Hovedetterforsker:
          • Hugues Jeanmart, MD
        • Ta kontakt med:
          • Hugues Jeanmart, MD
      • Québec, Quebec, Canada, G1V 4G5
        • Rekruttering
        • IUCPQ-ULaval
        • Ta kontakt med:
          • Eric Dumont, MD
        • Hovedetterforsker:
          • Eric Dumont, MD
      • Bonn, Tyskland, 53127
        • Aktiv, ikke rekrutterende
        • University Hospital Bonn Heart Center
      • Essen, Tyskland, 45147
        • Har ikke rekruttert ennå
        • West-German Heart and Vascular Center, University of Duisburg-Essen
        • Ta kontakt med:
          • Matthias Thielmann, MD, PhD
        • Hovedetterforsker:
          • Matthias Thielmann, MD, PhD
      • Hamburg, Tyskland, 20246
        • Rekruttering
        • University Medical Center Hamburg-Eppendorf
        • Ta kontakt med:
          • Simon Pecha, MD
        • Hovedetterforsker:
          • Simon Pecha, MD
    • Saxony
      • Leipzig, Saxony, Tyskland, 04289
        • Aktiv, ikke rekrutterende
        • Heart Center Leipzig
    • Thuringia
      • Jena, Thuringia, Tyskland, Germany
        • Rekruttering
        • University Hospital Jena
        • Ta kontakt med:
          • Torsten Doenst, MD, PhD
        • Hovedetterforsker:
          • Torsten Doenst, MD, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years at the time of enrolment,
  2. Open heart surgery in the last 10 days,
  3. Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
  4. Informed consent from either the patient or a substitute decision-maker.

Exclusion Criteria:

  1. Mechanical valve replacement,
  2. Antiphospholipid syndrome (triple positive),
  3. Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
  4. Known significant liver disease (Child-Pugh classification B and C),
  5. Left ventricular thrombus,
  6. Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
  7. Known contraindication for any DOAC or VKA,
  8. Women who are pregnant, breastfeeding, or of childbearing potential,
  9. Surgery including left ventricular assist device implantation or cardiac transplantation,
  10. Previously enrolled in this trial,
  11. Follow-up not possible,
  12. History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Direct Oral Anticoagulation (DOAC)

Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Andre navn:
  • Apixaban
  • Dabigatran
  • Edoxaban
  • Rivaroksaban
Placebo komparator: Vitamin K Antagonist

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

Andre navn:
  • Warfarin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Major Bleeding
Tidsramme: 30-Days post-randomization

Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis)

30-Days post-randomization

Sekundære resultatmål

Resultatmål
Tidsramme
Sammensatt av slag og systemisk arteriell emboli som ikke er sentralnervesystemet etter 30 og 90 dager.
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Store blødninger
Tidsramme: 90 dager etter randomisering
90 dager etter randomisering
Pleural eller perikardiell effusjon som krever drenering
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Systemisk arteriell emboli
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Iskemisk hjerneslag
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Dyp venetrombose
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Lungeemboli
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Lengde på postoperativt sykehusopphold
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Dødelighet av alle årsaker
Tidsramme: 6 måneder etter randomisering
6 måneder etter randomisering

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hjerteinfarkt
Tidsramme: 30-dager og 90-dager etter randomisering
30-dager og 90-dager etter randomisering
Sammenheng mellom subklinisk klaffetrombose og klinisk signifikant aortaklafftrombose, slag eller systemisk emboli
Tidsramme: 90 dager
90 dager
Minor Bleeding
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All bleeding (major plus minor)
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Valve Thrombosis
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Hemorrhagic stroke
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Stroke
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Arterial Thrombosis/thromboembolism
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis

30-Days and 90-Days post-randomization
Quality of Life - EQ-5D-5L
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: Measured by The EQ-5D-5L Questionnaire

30-Days and 90-Days post-randomization
Patient Satisfaction with Anticoagulant treatment
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire

30-Days and 90-Days post-randomization
Subclinical Valve Thrombosis on CT scan
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Mean Aortic Valve g=Gradient on echocardiogram
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Aortic Valve Reintervention
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Emilie Belley-Cote, MD, MSc, McMaster University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. juli 2021

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

24. februar 2020

Først innsendt som oppfylte QC-kriteriene

24. februar 2020

Først lagt ut (Faktiske)

26. februar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere